H
Hisashi Yamamoto
Researcher at Chubu University
Publications - 1496
Citations - 23715
Hisashi Yamamoto is an academic researcher from Chubu University. The author has contributed to research in topics: Catalysis & Enantioselective synthesis. The author has an hindex of 79, co-authored 1476 publications receiving 22398 citations. Previous affiliations of Hisashi Yamamoto include King Abdulaziz University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Chiral Molecular Recognition by Aluminum Tris(2,6-diphenylphenoxide) in an Asymmetric 1,4-Addition.
Journal ArticleDOI
Direct Coupling of Anilines with Aryllead Triacetates
Journal ArticleDOI
Development and Application of Versatile Bis-hydroxamic Acids for Catalytic Asymmetric Oxidation.
TL;DR: In this paper, the development and preliminary results of new designed C2-symmetric bis-hydroxamic acid (BHA) ligands were described and the application of the new ligands for vanadium-catalyzed asymmetric epoxidation of allylic alcohols as well as homoally-alignated alcohols.
Journal ArticleDOI
Entecavir Is Safe and Effective As Prophylaxis for Reactivation of Hepatitis B Virus in Allogeneic Stem Cell Transplant Recipients with Chronic or Resolved Viral Hepatitis B Infection
Masanori Tsuji,Hikari Ota,Aya Nishida,Kazuya Ishiwata,Hisashi Yamamoto,Go Yamamoto,Yuki Asano-Mori,Naoyuki Uchida,Koji Izutsu,Kazuhiro Masuoka,Atsushi Wake,Shigeyoshi Makino,Akiko Yoneyama,Shuichi Taniguchi +13 more
TL;DR: In conclusion, entecavir as prophylaxis for HBV reactivation in alloSCT recipients is considered to be safe and effective in this analysis.
Journal ArticleDOI
Prognostic Significance Of The Cytogenetic Evolution After The Hematopoietic Stem Cell Transplantation In Adult Acute Myeloid Leukemia
Mitsuhiro Yuasa,Naoyuki Uchida,Daisuke Kaji,Hikari Ota,Kazuya Ishiwata,Masanori Tsuji,Hisashi Yamamoto,Go Yamamoto,Yuki Asano-Mori,Shigeyoshi Makino,Akiko Yoneyama,Atsushi Wake,Koji Izutsu,Shuichi Taniguchi +13 more
TL;DR: Although durations from HSCT to relapse were comparable between group 1 and 2, survival time after relapse was significantly shorter in group 1 than in group 2, which indicates that cytogenetic clonal evolution may confer resistant characters against treatments, and needs novel therapeutic applications.